Combination of Dose Escalation with Technological Advances (intensity-modulated and Image-guided Radiotherapy) is Not Associated with Increased Morbidity for Patients with Prostate Cancer

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2011 Jul 27

PMID 21789739

Citations 33

Authors

Michael Pinkawa

Marc D Piroth

Richard Holy

Victoria Djukic

Jens Klotz

Barbara Krenkel

Michael J Eble

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim was to evaluate treatment-related morbidity after intensity-modulated (IMRT) and image-guided (IGRT) radiotherapy with a total dose of 76 Gy in comparison to conventional conformal radiotherapy (3DCRT) up to 70.2-72 Gy for patients with prostate cancer.

Patients And Methods: All patients were prospectively surveyed prior to, on the last day, as well as after a median time of 2 and 16 months after RT using a validated questionnaire (Expanded Prostate Cancer Index Composite). Criteria for the 78 matched pairs after IMRT vs. 3DCRT were patient age, use of antiandrogens, treatment volume (± whole pelvis), prognostic risk group, and urinary/bowel/sexual quality of life (QoL) before treatment.

Results: QoL changes after dose-escalated IMRT were found to be similar to QoL changes after 3DCRT in all domains. Only sexual function scores more than 1 year after RT decreased slightly more after 3DCRT in comparison to IMRT (mean 9 vs. 6 points; p = 0.04), with erections firm enough for intercourse in 14% vs. 30% (p = 0.03). Painful bowel movements were reported more frequently after 3DCRT vs. IMRT 2 months after treatment (≥ once a day in 10% vs. 1%; p = 0.03), but a tendency for higher rectal bleeding rates was found after IMRT vs. 3DCRT more than 1 year after RT (≥ rarely in 20% vs. 9%; p = 0.06).

Conclusion: Combination of dose escalation with technological advances (IMRT and IGRT) is not associated with increased morbidity for patients with prostate cancer.

Citing Articles

Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial.

Zwahlen D, Schroder C, Holer L, Bernhard J, Holscher T, Arnold W Clin Transl Radiat Oncol. 2024; 47:100786.

PMID: 38706726 PMC: 11067361. DOI: 10.1016/j.ctro.2024.100786.

Gastrointestinal Quality-of-Life Trajectories after Radiotherapy for Prostate Cancer-Which Patients Suffer from Persisting Problems?.

Pinkawa M Cancers (Basel). 2023; 15(17).

PMID: 37686572 PMC: 10486744. DOI: 10.3390/cancers15174295.

Erectile dysfunction and cancer: current perspective.

Madan R, Dracham C, Khosla D, Goyal S, Yadav A Radiat Oncol J. 2020; 38(4):217-225.

PMID: 33233032 PMC: 7785841. DOI: 10.3857/roj.2020.00332.

Quality of life more than 10 years after radiotherapy for localized prostate cancer-impact of time after treatment and prescription dose.

Pinkawa M, Gharib A, Schlenter M, Timm L, Eble M Qual Life Res. 2020; 30(2):437-443.

PMID: 33034812 PMC: 7886756. DOI: 10.1007/s11136-020-02639-7.

Application of rectal retractor for postprostatectomy salvage radiotherapy of prostate cancer: A case report and literature review.

Ghaffari H, Ardekani M, Molana S, Haghparast M, Sanei M, Mahdavi S Clin Case Rep. 2019; 7(11):2102-2107.

PMID: 31788259 PMC: 6878068. DOI: 10.1002/ccr3.2430.

References

Michalski J, Winter K, Purdy J, Parliament M, Wong H, Perez C . Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005; 62(3):706-13. DOI: 10.1016/j.ijrobp.2004.11.028. View

Vordermark D, Schwab M, Ness-Dourdoumas R, Sailer M, Flentje M, Koelbl O . Association of anorectal dose-volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate. Radiother Oncol. 2003; 69(2):209-14. DOI: 10.1016/j.radonc.2003.07.002. View

Pinkawa M, Piroth M, Holy R, Fischedick K, Klotz J, Szekely-Orban D . Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison. Int J Radiat Oncol Biol Phys. 2010; 81(1):23-8. DOI: 10.1016/j.ijrobp.2010.05.054. View

Pinkawa M, Piroth M, Fischedick K, Holy R, Klotz J, Nussen S . Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer. Strahlenther Onkol. 2009; 185(11):724-30. DOI: 10.1007/s00066-009-2008-6. View

Arruda Viani G, Stefano E, Afonso S . Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009; 74(5):1405-18. DOI: 10.1016/j.ijrobp.2008.10.091. View

Goldner G, Tomicek B, Becker G, Geinitz H, Wachter S, Zimmermann F . Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys. 2006; 67(1):78-83. DOI: 10.1016/j.ijrobp.2006.08.055. View

Wei J, Dunn R, Litwin M, Sandler H, Sanda M . Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56(6):899-905. DOI: 10.1016/s0090-4295(00)00858-x. View

De Meerleer G, Vakaet L, De Gersem W, De Wagter C, De Naeyer B, De Neve W . Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys. 2000; 47(3):639-48. DOI: 10.1016/s0360-3016(00)00419-3. View

van der Wielen G, van Putten W, Incrocci L . Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys. 2007; 68(2):479-84. DOI: 10.1016/j.ijrobp.2006.12.015. View

10.

de Crevoisier R, Tucker S, Dong L, Mohan R, Cheung R, Cox J . Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 62(4):965-73. DOI: 10.1016/j.ijrobp.2004.11.032. View

11.

Zelefsky M, Levin E, Hunt M, Yamada Y, Shippy A, Jackson A . Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70(4):1124-9. DOI: 10.1016/j.ijrobp.2007.11.044. View

12.

Partin A, Mangold L, Lamm D, Walsh P, Epstein J, Pearson J . Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001; 58(6):843-8. DOI: 10.1016/s0090-4295(01)01441-8. View

13.

Ghadjar P, Gwerder N, Manser P, Vock J, Madlung A, Mini R . High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer. Strahlenther Onkol. 2010; 186(12):687-92. DOI: 10.1007/s00066-010-2180-8. View

14.

Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L . Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 57(4):953-62. DOI: 10.1016/s0360-3016(03)00665-5. View

15.

Guckenberger M, Ok S, Polat B, Sweeney R, Flentje M . Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol. 2010; 186(10):535-43. DOI: 10.1007/s00066-010-2144-z. View

16.

Pinkawa M, Siluschek J, Gagel B, Piroth M, Demirel C, Asadpour B . Postoperative radiotherapy for prostate cancer : evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy). Strahlenther Onkol. 2007; 183(1):23-9. DOI: 10.1007/s00066-007-1588-2. View

17.

Al-Mamgani A, van Putten W, Heemsbergen W, van Leenders G, Slot A, Dielwart M . Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72(4):980-8. DOI: 10.1016/j.ijrobp.2008.02.073. View

18.

Goldner G, Dimopoulos J, Kirisits C, Potter R . Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol. 2009; 185(7):438-45. DOI: 10.1007/s00066-2009-2033-5. View

19.

Akimoto T, Muramatsu H, Takahashi M, Saito J, Kitamoto Y, Harashima K . Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2004; 60(4):1033-9. DOI: 10.1016/j.ijrobp.2004.07.695. View

20.

Pinkawa M, Holy R, Piroth M, Fischedick K, Schaar S, Szekely-Orban D . Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study. Radiat Oncol. 2010; 5:27. PMC: 2857853. DOI: 10.1186/1748-717X-5-27. View